Lantern Pharma Inc SEC Filings

Lantern Pharma (LTRN) filed its Q3 2025 10‑Q, reporting a net loss of $4,177,423 for the quarter and $13,045,221 for the nine months ended September 30, 2025. Operating expenses fell year over year as research and development declined to $2,436,971 in Q3 (from $3,716,646), while general and administrative rose to $1,912,829. Interest income was $100,921 and other income, net was $71,456.

Cash and cash equivalents were $8,389,486 and marketable securities were $3,973,090 at September 30, 2025. Working capital was approximately $9,421,000. Management states that existing cash, cash equivalents, and marketable securities are expected to fund operations until approximately late June 2026 to mid August 2026, and the filing raises “substantial doubt” about the company’s ability to continue as a going concern without substantial additional funding.

To bolster liquidity, Lantern entered an at‑the‑market program of up to $15,530,000. In Q3, it sold 212,444 shares for gross proceeds of $989,061 and paid $29,672 in commissions; from October 1 to the report date, it sold an additional 144,204 shares for gross proceeds of $634,333, with $19,030 in commissions.

Lantern Pharma Inc. filed a Form 8-K reporting voting tallies for one or more matters. The record shows totals including 5,189,274 votes and several vote-category counts such as 2,212,199, 2,214,833, 2,213,670, 2,213,088, and smaller counts listed as Against 758,870, Against 43,732, and Abstain 29,603 and 26,426. The filing names Lantern Pharma Inc. as a Delaware corporation and is signed by David R. Margrave, Chief Financial Officer.

Lantern Pharma (LTRN) director Vijay Chandru amended two outstanding stock options on 09/19/2025, replacing earlier awards with new options priced at $5.04 per share. The original options were granted on 06/15/2020 (9,135 underlying shares, originally $15 exercise price, expiration 06/14/2030) and 11/04/2021 (3,200 underlying shares, originally $10.32 exercise price, expiration 11/03/2031). The amendments cancelled the old options and granted replacement options covering the same share amounts, leaving Mr. Chandru with options for a total of 12,335 underlying shares exercisable under the stated expirations.

Panna Sharma, President & CEO and a director of Lantern Pharma Inc. (LTRN), amended an outstanding stock option originally granted on 06/15/2020. The amendment, recorded with a transaction date of 09/19/2025, canceled the prior option with a $15 exercise price covering 76,628 underlying shares and replaced it with a new option covering the same 76,628 shares at a reduced exercise price of $5.04. The option retains its original exercisability and expiration schedule (vested schedule described in the filing) and the replacement option shows 76,628 shares beneficially owned following the amendment. The form is signed by Ms. Sharma on 09/22/2025.

Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.

D. Jeffrey Keyser, a director of Lantern Pharma Inc. (LTRN), reported amendments to two outstanding stock options on a Form 4 covering transactions dated 09/19/2025. Each amendment cancelled an "old" option and granted a replacement option with a reduced exercise price while retaining the original grant dates and expiration dates. The June 15, 2020 option for 9,135 shares was changed from a $15.00 exercise price to $5.04 and remains exercisable through 06/14/2030. The November 4, 2021 option for 3,200 shares was changed from a $10.32 exercise price to $5.04 and remains exercisable through 11/03/2031. Both options vest on the original monthly 36-month schedules.

Lantern Pharma director and Chief Financial Officer David R. Margrave reported amendments to two previously granted stock options that reduced the exercise prices and replaced the canceled options with new options. One option originally granted June 15, 2020 for 78,300 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 06/14/2030, resulting in a held position of 78,300 underlying shares. A second option originally granted October 29, 2021 for 26,100 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 10/28/2031, resulting in a held position of 26,100 underlying shares. The filing is limited to these option amendments and the reporting person’s relationship as Director and Chief Financial Officer.

Lantern Pharma Inc. (LTRN): Director David S. Silberstein reported amendments to two outstanding stock options on 09/19/2025 that reduced the exercise prices and replaced the prior options. The first option originally granted 06/15/2020 (exercise price $15) for 9,135 shares was cancelled and replaced with a $5.04 option exercisable through 06/14/2030, leaving 9,135 underlying shares beneficially owned. The second option originally granted 11/04/2021 (exercise price $10.32) for 3,200 shares was cancelled and replaced with a $5.04 option exercisable through 11/03/2031, leaving 3,200 underlying shares beneficially owned. The filings note standard monthly vesting schedules for each original grant and the form is signed 09/22/2025.

Lantern Pharma (LTRN) director Lee T. Schalop was granted a stock option award for 5,000 shares under the companys Amended and Restated 2018 Equity Incentive Plan. The option has an exercise price of $4.46 and was granted with a transaction date of 08/19/2025. The award becomes exercisable in equal monthly increments over a 36-month vesting period commencing 09/19/2025 and expires 08/18/2035. The filing reports 5,000 underlying shares held directly following the grant. The Form 4 was submitted by the reporting person, who is identified as a director of the issuer.